Citation Information :
Peshattiwar V. The Fondaparinux Paradox: Fondaparinux-Related Heparin-Induced Thrombocytopenia. Indian J Crit Care Med 2018; 22 (2):116-118.
Fondaparinux, a pentasaccharide administered for heparin-induced thrombocytopenia (HIT), can lead to the occurrence of thrombocytopenia. This patient underwent aortic stent graft placement for Salmonella paratyphi A-infected abdominal aortic aneurysm. Fondaparinux was administered for anticoagulation that led to a dramatic decline in his platelet counts. Investigations revealed HIT profile, PF4/heparin by particle gel immunoassay to be positive. Fondaparinux, a prescribed anticoagulant for HIT can paradoxically predispose to thrombocytopenia.
Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-14.
Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-6.
Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-5.
Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood Coagul Fibrinolysis 2011;22:76-8.
Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE, et al. Combination of 4Ts score and PF4/H-paGIA for diagnosis and management of heparin-induced thrombocytopenia: Prospective cohort study. Blood 2015;126:597-603.
